NV
$20.89
+0.19
(+0.92%)
As of Oct 22, 2026, 9:30 PM EDT · cached
Price history
Nuvectis Pharma Inc (NVCT) is trading up at $20.89 (+0.92%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: February 4, 2022 · $5.00 offering · NASDAQ · View IPO details →
Nuvectis Pharma Inc net income history (FY2021–FY2025)
Net income
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Operating income | −$12.9M | −$19.2M | −$22.9M | −$19.8M | −$27.6M |
| Net income | −$12.9M | −$19.1M | −$22.3M | −$19.0M | −$26.4M |
| EPS (diluted) | −$3.02 | −$1.51 | −$1.43 | −$1.11 | −$1.32 |
| Balance sheet | |||||
| Cash and equivalents | $5.74M | $20.0M | $19.1M | $18.5M | $31.6M |
| Total assets | $6.66M | $20.4M | $19.2M | $18.6M | $31.7M |
| Total liabilities | $2.42M | $6.19M | $6.98M | $8.89M | $13.3M |
| Shareholders' equity | −$11.0M | $14.2M | $12.2M | $9.71M | $18.4M |
| Cash flow | |||||
| Operating cash flow | −$9.50M | −$13.6M | −$16.0M | −$12.2M | −$16.0M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$4.36M | −$6.45M | −$5.57M | −$6.59M | −$7.79M | −$7.62M | −$6.26M | −$7.20M |
| Net income | −$4.15M | −$6.25M | −$5.33M | −$6.33M | −$7.46M | −$7.31M | −$6.05M | −$7.02M |
| EPS (diluted) | −$0.24 | −$0.36 | −$0.27 | −$0.30 | −$0.44 | −$0.31 | −$0.26 | −$0.30 |
| Balance sheet | ||||||||
| Cash and equivalents | $17.2M | $18.5M | $29.9M | $26.8M | $35.4M | $31.6M | $25.1M | $22.2M |
| Total assets | $17.3M | $18.6M | $30.1M | $27.0M | $35.6M | $31.7M | $25.4M | $22.4M |
| Total liabilities | $6.32M | $8.89M | $9.19M | $10.1M | $11.6M | $13.3M | $11.2M | $13.3M |
| Shareholders' equity | $11.0M | $9.71M | $21.0M | $16.9M | $24.0M | $18.4M | $14.2M | $9.08M |
| Cash flow | ||||||||
| Operating cash flow | −$2.40M | −$2.46M | −$4.17M | −$3.37M | −$4.49M | −$3.97M | −$6.51M | −$4.53M |
From Nuvectis Pharma Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Nuvectis Pharma Inc
- Headquarters
- Fort Lee, New Jersey From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International